Media & Press2019-09-17T16:08:49-04:00

    Bexion Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation

    September 30, 2020|

    FOR IMMEDIATE RELEASE [Covington, KY] September 30, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that the Federal Drug Administration (FDA) has granted the company’s request for rare pediatric disease designation for BXQ-350, Bexion’s lead therapeutic, for the treatment of diffuse intrinsic pontine glioma (DIPG) and ... Read More

      Bexion Pharmaceuticals, Inc. to Present Clinical and Pre-Clinical Data at 2020 SNO Annual Meeting

      September 16, 2020|

      FOR IMMEDIATE RELEASE [Covington, KY: September 16, 2020] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cures for cancer announced today it will present clinical and pre-clinical electronic posters with audio presentations at the Society of Neuro-Oncology (SNO) annual virtual conference to be held November 19-21, 2020. "We ... Read More

        Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020

        May 13, 2020|

        For Immediate Release, Covington, KY May 13, 2020 Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Presentation Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial. ... Read More

          Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA

          May 6, 2020|

          FOR IMMEDIATE RELEASE [Covington, KY May 6, 2020] Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 ... Read More

            Bexion Pharmaceuticals, Inc. to Present at the Precision Medicine World Conference (PMWC) 2020

            January 15, 2020|

            FOR IMMEDIATE RELEASE [Covington, KY~ January 15, 2020] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 in the Immunotherapy Showcase of the PMWC 2020 conference, ... Read More

              Cincinnati Enquirer: 8 Cincinnati biotech companies with big steps to watch in 2020

              January 1, 2020|

              Excerpt: Cincinnati has become a nurturing place for bright ideas in biotechnology, and 2020 could bring big advancements. The Cincinnati USA Regional Chamber of Commerce estimates the industry contributes more than $3 billion to the area economy. Nearly 800 locations employ more than 13,000 workers who are making average salaries of about $100,000 a ... Read More

                Bexion Pharmaceuticals, Inc. To Present Clinical Data at 2019 NORD Annual Meeting

                September 4, 2019|

                Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for ... Read More

                  Bexion Pharmaceuticals Experiences Robust Enrollment of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

                  March 5, 2019|

                  FOR IMMEDIATE RELEASE Covington, KY ~ March 5, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites. In the first few weeks of opening Part 3, over 20 GI and ... Read More

                    Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

                    February 22, 2019|

                    FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer. This trial was designed to determine the maximum tolerated dose of BXQ-350 and to characterize its safety and pharmacokinetics. The Phase I ... Read More

                      Dr. Ray Takigiku Honored as Finalist at the 2019 Healthcare Hero Awards

                      |

                      FOR IMMEDIATE RELEASE Covington, KY – 22 February 2019 Dr. Ray Takigiku, Founder and CEO of Bexion Pharmaceuticals, Inc. was honored as a finalist in the category of “Entrepreneur” of the Year by the Cincinnati Business Courier at the 2019 Healthcare Hero Awards Celebration. These annual awards honor individuals and organizations that have improved the ... Read More

                        Bexion Pharmaceuticals, Inc. Presents Clinical Data at 2018 SNO Annual Meeting

                        November 19, 2018|

                        FOR IMMEDIATE RELEASE Covington, KY ~ 19 November 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster review and a second case study poster were presented at the Society of Neuro-Oncology (SNO) Annual Meeting held November 16-18 in New ... Read More

                          Bexion Pharmaceuticals, Inc. Represented at 15th Annual BioNetwork Partnering Summit

                          October 18, 2018|

                          National Cancer Institute (NCI) Selects Bexion as a Presenting Company FOR IMMEDIATE RELEASE [Covington, KY ~ October 18, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announces that Dr. Ray Takigiku, Founder and CEO of the Company presented recently at the 15th Annual BioNetwork Partnering Summit, held ... Read More

                            Bexion Pharmaceuticals, Inc. Announces Grant from CancerFree KIDS

                            June 19, 2018|

                            CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 Sometimes things come full circle. Fourteen years ago, CancerFree KIDS awarded its very first research grant to a young investigator at Cincinnati Children’s Hospital Medical Center (CCHMC) to study a long shot idea that no one ... Read More

                              Bexion Pharmaceuticals, Inc. Announces Data at 2018 ASCO Annual Meeting from Ongoing Phase I BXQ-350 Clinical Trial

                              June 12, 2018|

                              FOR IMMEDIATE RELEASE Covington, KY ~ June 12, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, discussed data from 17 patients enrolled in the Phase Ia portion of its ongoing Phase I Safety Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting Poster Session, held in ... Read More

                                Bexion Pharmaceuticals, Inc. To Present Clinical Data at 2018 ASCO Annual Meeting

                                May 22, 2018|

                                FOR IMMEDIATE RELEASE Covington, KY ~ May 22,2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature one clinical poster presentation and three online publications at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 1-5 in Chicago, IL. The ... Read More

                                  Bexion Pharmaceuticals, Inc. Presentations Accepted at 2018 ASCO Annual Meeting

                                  April 16, 2018|

                                  FOR IMMEDIATE RELEASE Covington, KY April 16, 2018 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain tumors, announced today that the four abstracts submitted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago, Illinois have all been accepted. One of the accepted presentations ... Read More

                                    Bexion Pharmaceuticals, Inc. to Present at the 25th Annual Meeting of Future Leaders in the BioTech Industry

                                    February 14, 2018|

                                    FOR IMMEDIATE RELEASE [Covington, KY ~ February 14, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 at the Future Leaders in the BioTech Industry ... Read More

                                      Bexion Pharmaceuticals Honoree at American Cancer Society Annual Ball

                                      November 16, 2016|

                                      COVINGTON, KY. November 16, 2016 – Bexion Pharmaceuticals was awarded the “Medical Professional Award” at the American Cancer Society’s Annual Striders’ Ball held on November 5, 2016. This is the first time the honor has been bestowed on a company versus an individual medical professional. “We are greatly honored to have been nominated, and to ... Read More

                                        Bexion Pharmaceuticals Finalist for Cancer Support Community’s Inspiration in Cancer Research Award

                                        November 8, 2016|

                                        COVINGTON, KY. November 8, 2016 – Bexion Pharmaceuticals was honored as a finalists for the “2016 Inspiration in Cancer Research Award” at the Cancer Support Community’s (CSC) annual Evening of Hope Gala, held on October 29, 2016. “The Bexion team is honored to be a finalist for the CSC annual Inspiration Award,” stated Dr. Ray ... Read More

                                          Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute

                                          September 20, 2016|

                                          FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY. September 20, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) and the University of Cincinnati Cancer Institute (UCCI) announced today the dosing of the first patient in the Phase I trial of BXQ-350, a novel anti-cancer therapeutic agent. This open-label trial will include adult patients with advanced solid ... Read More

                                            Bexion Pharmaceuticals and CTI Clinical Trial and Consulting Services Announce Collaboration on First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

                                            September 9, 2016|

                                            FOR IMMEDIATE RELEASE [Cincinnati, OH ~ September 8, 2016] Bexion Pharmaceuticals (Bexion) and CTI Clinical Trial and Consulting Services (CTI) announce their collaboration on the First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. The FDA recently cleared Bexion’s application to initiate the open-label trial that will include adult patients with advanced ... Read More

                                              Bexion Pharmaceuticals Receives FDA Clearance For the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer

                                              July 18, 2016|

                                              FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, July 18, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) announced today that the U.S. Food and Drug Administration (FDA) cleared Bexion’s application to initiate a First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. This open-label trial will include adult patients with advanced solid ... Read More

                                                Bexion Pharmaceuticals Wins 2015 Tibbetts Award From the Small Business Administration

                                                June 1, 2015|

                                                FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, June 1, 2015 -- Bexion Pharmaceuticals LLC announced that the Small Business Administration (SBA) has awarded the Company the prestigious Tibbetts Award, recognizing Bexion as a “Model of Excellence” for the Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Awarded ... Read More

                                                  Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme from FDA

                                                  February 16, 2015|

                                                  FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, Feb. 16, 2015 -- Bexion Pharmaceuticals LLC announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for Saposin C, active  ingredient in its proprietary drug BXQ-350 for the potential treatment of glioblastoma multiforme. The FDA’s Office of ... Read More